To test if COX-2 inhibition would enhance the efficacy of chemoimmunotherapy in a different tumor model, using a different CTX drug, we treated CT26 colorectal tumors using 5-FU, commonly used in first-line CTX regimens for the treatment of colorectal cancer (Supplementary Fig. 9a). Here, PTGS2 is linked to neoplasm.